AstraZeneca, Sophia Genetics Expand Cancer Detection Collaboration
MT Newswires Live
Yesterday
AstraZeneca (AZN) has expanded its partnership with Sophia Genetics (SOPH) to develop a next-generation sequencing offering for better detection of genetic mutations in breast and prostate cancer, Sophia Genetics said Monday.
Under the partnership, artificial intelligence algorithms by Sophia Genetics will analyze mutations in the full PTEN gene on the sequencing offering.
Sophia Genetics also said it plans to roll out a program for select clinical laboratories to validate sensitivity in a real-world setting, with commercial availability expected in 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.